MiMedx Group (MDXG) Weak On High Volume
Trade-Ideas LLC identified
(
) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified MiMedx Group as such a stock due to the following factors:
- MDXG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $7.0 million.
- MDXG has traded 381,818 shares today.
- MDXG is trading at 9.37 times the normal volume for the stock at this time of day.
- MDXG is trading at a new low 5.12% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in MDXG with the Ticky from Trade-Ideas. See the FREE profile for MDXG NOW at Trade-Ideas
More details on MDXG:
MiMedx Group, Inc. develops, processes, and markets regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. MDXG has a PE ratio of 46. Currently there are 5 analysts that rate MiMedx Group a buy, no analysts rate it a sell, and 1 rates it a hold.
The average volume for MiMedx Group has been 903,600 shares per day over the past 30 days. MiMedx Group has a market cap of $852.3 million and is part of the health care sector and health services industry. The stock has a beta of 1.03 and a short float of 19.1% with 20.36 days to cover. Shares are down 18.7% year-to-date as of the close of trading on Monday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates MiMedx Group as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and a generally disappointing performance in the stock itself.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 19.6%. Since the same quarter one year prior, revenues rose by 30.9%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. In comparison to other companies in the Biotechnology industry and the overall market on the basis of return on equity, MIMEDX GROUP INC has underperformed in comparison with the industry average, but has greatly exceeded that of the S&P 500.
- Net operating cash flow has significantly decreased to -$0.98 million or 123.20% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 70.7% when compared to the same quarter one year ago, falling from $4.09 million to $1.20 million.
- You can view the full MiMedx Group Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.